As it faces up to the sales decline of former flagship drug Rebif (interferon beta-1a), Merck KGAA is banking on new multiple sclerosis therapies to help it come through 2018 which, according to CEO Stefan Oschmann, will be a year of transition.
Speaking at the German group's annual press conference in Darmstadt on March 8, he described 2017 as "a year of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?